Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class ASSE: 600196

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Acceptance of the Drug Registration Application of Controlled Subsidiary

Sep 12, 2026 · Issued by Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Sep 12, 2026

Announcement on Acceptance of the Drug Registration Application of Controlled Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on the Public Disclosure and Review Opinion of the List of Participants for the Reserved Grant under the 2025 A-Share Stock Option Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of DirectorsSep 9
Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 BillionSep 6
"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Extension of Loans to a Controlled Subsidiary and Related Party TransactionSep 5
"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on a Controlled Subsidiary's Drug Obtaining Registration Approval for a New IndicationSep 4

All Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A news releases